314 related articles for article (PubMed ID: 37071254)
1. Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases.
Rader RK; Anders CK; Lin NU; Sammons SL
Curr Treat Options Oncol; 2023 Jun; 24(6):611-627. PubMed ID: 37071254
[TBL] [Abstract][Full Text] [Related]
2. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
[TBL] [Abstract][Full Text] [Related]
3. Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
Dempsey N; Sandoval A; Mahtani R
Curr Treat Options Oncol; 2023 Sep; 24(9):1120-1137. PubMed ID: 37428332
[TBL] [Abstract][Full Text] [Related]
4. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
Dent RA; Cescon DW; Bachelot T; Jung KH; Shao ZM; Saji S; Traina TA; Vukovic P; Mapiye D; Maxwell MJ; Schmid P; Cortés J
Future Oncol; 2023 Nov; 19(35):2349-2359. PubMed ID: 37526149
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.
Kabraji S; Ni J; Sammons S; Li T; Van Swearingen AED; Wang Y; Pereslete A; Hsu L; DiPiro PJ; Lascola C; Moore H; Hughes M; Raghavendra AS; Gule-Monroe M; Murthy RK; Winer EP; Anders CK; Zhao JJ; Lin NU
Clin Cancer Res; 2023 Jan; 29(1):174-182. PubMed ID: 36074155
[TBL] [Abstract][Full Text] [Related]
6. Systemic management of brain metastases in HER2+ breast cancer in 2022.
Alder L; Sammons S; Van Swearingen AED; Anders CK
Clin Adv Hematol Oncol; 2022 May; 20(5):325-336. PubMed ID: 35579591
[TBL] [Abstract][Full Text] [Related]
7. Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer.
Noteware L; Broadwater G; Dalal N; Alder L; Herndon Ii JE; Floyd S; Giles W; Van Swearingen AED; Anders CK; Sammons S
Breast Cancer Res Treat; 2023 Jan; 197(2):425-434. PubMed ID: 36403183
[TBL] [Abstract][Full Text] [Related]
8. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Curigliano G; Mueller V; Borges V; Hamilton E; Hurvitz S; Loi S; Murthy R; Okines A; Paplomata E; Cameron D; Carey LA; Gelmon K; Hortobagyi GN; Krop I; Loibl S; Pegram M; Slamon D; Ramos J; Feng W; Winer E
Ann Oncol; 2022 Mar; 33(3):321-329. PubMed ID: 34954044
[TBL] [Abstract][Full Text] [Related]
9. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
[TBL] [Abstract][Full Text] [Related]
10. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
[TBL] [Abstract][Full Text] [Related]
11. New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023.
Banys-Paluchowski M; Krawczyk N; Stickeler E; Müller V; Fehm T
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):54-61. PubMed ID: 36239554
[TBL] [Abstract][Full Text] [Related]
12. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
Fenton MA; Tarantino P; Graff SL
Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
14. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
Dormann C
Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapy for metastatic HER2-positive breast cancer.
Bredin P; Walshe JM; Denduluri N
Semin Oncol; 2020 Oct; 47(5):259-269. PubMed ID: 32896428
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone.
Pearson J; Khan A; Bhogal T; Wong H; Law A; Mills S; Santamaria N; Bishop J; Cliff J; Errington D; Hall A; Hart C; Malik Z; Sripadam R; Innes H; Flint H; Langton G; Ahmed E; Jackson R; Palmieri C
ESMO Open; 2023 Dec; 8(6):102033. PubMed ID: 37866031
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.
Bartsch R; Berghoff AS; Furtner J; Marhold M; Bergen ES; Roider-Schur S; Starzer AM; Forstner H; Rottenmanner B; Dieckmann K; Bago-Horvath Z; Haslacher H; Widhalm G; Ilhan-Mutlu A; Minichsdorfer C; Fuereder T; Szekeres T; Oehler L; Gruenberger B; Singer CF; Weltermann A; Puhr R; Preusser M
Nat Med; 2022 Sep; 28(9):1840-1847. PubMed ID: 35941372
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
Bartsch R
Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
[TBL] [Abstract][Full Text] [Related]
20. Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer.
Eberst L; Bailleux C; Bachelot T
Curr Opin Oncol; 2020 Nov; 32(6):555-560. PubMed ID: 32890023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
